
After a rollercoaster year, French biotech business Valneva is experiencing somewhat of a comeback on the Covid-19 front, after having presented promising phase III data for its Covid-19 vaccine. Investors have rewarded it by sending Valneva stock up by more than 30 percent.
The new data comes just a month after the UK government canceled a previous vaccine supply deal with Valneva, concerning millions of doses.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app